CD68 and neoplasm: No significant correlation was observed between the density of CD68<sup>+</sup> TAMs and disease stage (OR= 1.433, 95% CI: 0.656-3.130, P = 0.366), IPI (OR= 1.391, 95% CI: 0.573-3.379, P = 0.466), OS (HR=0.929, 95% CI: 0.607-1.422, P = 0.734) or PFS (HR= 0.756, 95% CI: 0.415-1.379, P = 0.362) in DLBCL patients.<h4>Conclusion</h4>This meta-analysis demonstrated that high density of M2 TAMs in the tumor microenvironment was a robust predictor of adverse outcome for DLBCL patients.<h4>Systematic review registration</h4>https://www.crd.york.ac.uk/PROSPERO, identifier CRD42022343045.